Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as APL-3007, pegcetacoplan (APL-2), APL-3007, pegcetacoplan
APL-3007 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 (APL-3007 Dose/Frequency 1 ) | EXPERIMENTAL | APL-3007 SC + pegcetacoplan (APL-2) |
| Group 2 (APL-3007 Dose/Frequency 2) | EXPERIMENTAL | APL-3007 + pegcetacoplan (APL-2) |
| Group 3 (placebo) | PLACEBO_COMPARATOR | Placebo SC + pegcetacoplan (APL-2) |
| Name | Type | Description |
|---|---|---|
| APL-3007, pegcetacoplan (APL-2) | DRUG | Complement C3 inhibitor |
| Placebo, Syfovre | OTHER | Complement C3 Inhibitor |
Inclusion Criteria: * The study eye must meet all inclusion criteria. If both eyes meet the inclusion criteria, the eye with better normal luminance visual acuity at the screening visit will be designated as the study eye. If both eyes have the same visual acuity, the right eye will be used as the ...
APL-3007 is an investigational small molecule being studied for the treatment of Geographic Atrophy Secondary to Age-related Macular Degeneration. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
APL-3007 targets complement component C3, a protein involved in the complement cascade. By targeting C3, APL-3007 is designed to modulate the complement system, which is implicated in the progression of Geographic Atrophy Secondary to Age-related Macular Degeneration.
APL-3007 is being developed by Apellis Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol APLS.
APL-3007 is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency.
APL-3007 is being evaluated in a Phase 2 clinical trial with the identifier NCT07215390. This is a randomized, double-blind, placebo-controlled study enrolling approximately 240 patients with Geographic Atrophy Secondary to Age-related Macular Degeneration in the United States.
APL-3007 is also known as pegcetacoplan (APL-2). The drug is being studied in combination with Syfovre/pegcetacoplan (APL-2) in the ongoing Phase 2 clinical trial.